The book will be arranged into two sections; Basic Science and Clinical Science, to enable the scientist and the more clinically focused reader to readily access the required information. Topics covered will include lipoprotein structure, function and metabolism, with particular emphasis on diabetes-related changes, lipoprotein related research techniques, clinically available research tools, recent major diabetes and lipid related clinical trials, effects of lifestyle and glycemic control on lipoproteins, and the use of the major lipid modifying medications.

The primary goal of the guideline is to improve the quality of care and the outcome in people with type 2 diabetes in low-resource settings. The guideline provides a basis for development of simple algorithms for management of diabetes with essential medicines and technology available in first-contact health services in low-resource settings. It recommends a set of basic interventions to integrate management of diabetes into primary health care. The recommendations are limited to patients with type 2 diabetes, as the more complex management of type 1 diabetes requires more specialized care.The target users are health care professionals responsible for developing diabetes treatment protocols which will be used by health care staff in primary care units in low-resource settings. A guideline development group was constituted, which included external experts and WHO staff.

The world is faced with an epidemic of metabolic diseases such as obesity and type 2 diabetes. This is due to changes in dietary habits and the decrease in physical activity. Exercise is usually part of the prescription, the first line of defense, to prevent or treat metabolic disorders. However, we are still learning how and why exercise provides metabolic benefits in human health. This open access volume focuses on the cellular and molecular pathways that link exercise, muscle biology, hormones and metabolism. This will include novel "myokines" that might act as new therapeutic agents in the future.

This timely and clinically oriented book uniquely addresses the entire spectrum of treatment for severe obesity and diabetes. It thoroughly examines all aspects from robotic surgery to cell therapy, from the latest antidiabetic drugs to endoscopic procedures and devices, from appetite-inhibiting signals and nutrients to gastric arterial embolization. It offers objective and authoritative information for practicing professionals; not only are successful interventions discussed and updated, but cutting-edge and experimental pathways are also anticipated. Obesity is the foremost nutritional challenge worldwide. Its companion is type-2 diabetes, the most prevalent metabolic disease. Together they represent the diabesity epidemic, which is draining resources, overwhelming healthcare facilities, and impacting life expectancy and quality of life everywhere. No country has been spared, and most medical specialties have been affected. Many books focus on the surgical options for obesity and diabetes, namely bariatric and metabolic operations. Information on the clinical and pharmacological treatment is also available, conveyed by standard texts on internal medicine and endocrinology. Yet endoscopic maneuvers and prostheses, cell therapy for diabetes, and other innovative approaches are hard to come by, as conventional texts overlook such therapies. This timely publication bridges the gaps between all different therapeutic options, also covering advances in the conservative, surgical and parasurgical domains. This book will appeal to seasoned specialists, students and healthcare professionals in training alike.